From 1 September 2025, eligibility criteria now includes those who are severely immunosuppressed (SIS) and aged 18-49 years (previously only included SIS patients 50 years +). Patients should receive Shingrix® (2-dose schedule), the second dose administered 8 weeks to 6 months after the first dose. Eligible patients who do not receive the second dose within six months, however, can still receive the second vaccine later, there is no need to start again. Severely immunosuppressed individuals who had received Zostavax® prior to developing immunosuppression should be offered 2 doses of Shingrix®.
Practices are required to undertake call/recall for patients in the severely immunosuppressed cohort as they become eligible for the programme.
Monthly automated claim via CQRS – the extraction will check for first or second vaccine codes but will only extract claim if the required time period has passed between the 2 vaccines.
